it is designed to accommodate multiplex assays as the Company expands its future suite of products to include additional respiratory, STI and other infectious diseases.", While the Call says nary a peep about Eikon, it has plenty to say about Co-Dx YourTest, including that: Eikon has morphed into the "Co-Dx YourTest". Upon reading the Call it seems that Co-Diagnostics has settled on a new name for its Eikon test without bothering to communicate a name change. Why it was not mentioned, even in passing during the Call, was a mystery. It prominently featured the following picture of its device:Ĭo-Diagnostics' Eikon testing device () The latest entry, dated took me to an enthusiastic write-up on Co-Diagnostic's web site, headlined, "Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology". Products built on the Eikon PCR platform are subject to FDA review and are not currently for sale. ![]() The presentation, titled "Co-Diagnostics' New Eikon PCR Platform," will be demonstrating how the Company's new platform technology is designed to provide inexpensive, fast, and accurate PCR results for at-home and point-of-care testing. Kirk Ririe, President of the Company's subsidiary, will be presenting in the conference's At-Home & Point-of-Care Diagnostics track on Monday, February 21 from 12:20 pm to 12:50 pm. The following entry encouraged me that Eikon had not just been abandoned:Ĭo-Diagnostics CEO Dwight Egan and Dr. What became of Eikon? I googled "Co-Diagnostics Eikon" on as I write. My appetite having been thoroughly whetted by previous discussions, an Eikon update was the first thing I looked for in the Call when it was released on. The Call dropped all mention of Eikon, raising questions safe schools, safe workplaces, restaurants, hotels, ships, entertainment venues. The Eikon platform goal was to provide fast, cheap and accurate results, initially for Covid-19 with multiplexing potential to extend its coverage.Ĭo-Diagnostics anticipated Eikon having a role in: Here was a versatile testing solution that fit into a broad array of testing scenarios.Įikon had featured prominently (23 hits for the word "Eikon") in Co-Diagnostics' Q3 earnings call. Wainwright presentation ()Įikon would provide an excellent encore for Co-Diagnostics to succeed as COVID-19 moved from its pandemic to an endemic phase. It included the following Eikon specifications slide:Įikon specification slide from H. This was the issue I addressed in Fences, where I enthused about Co-Diagnostics' newest product, its Eikon testing platform. The challenge for Co-Diagnostics was to maintain its mojo if and when the pandemic wound down, as indeed it currently seems to be doing. This early success catapulted it to its A+ quant ratings. As discussed in A+ Student it was at the forefront in terms of approval for its COVID-19 testing technology. Co-Diagnostics developed Eikon testing platform as a bridge to endemic COVIDĬo-Diagnostics was an effective COVID-19 testing pioneer. I am less so after reviewing its recently released Q4 2021 earnings call (the "Call") as I will explain. I have been optimistic on the company's prospects. The first was 03/2021's "Co-Diagnostics: A+ Student Faces New Tests" ("A+ Student") I followed it with 01/2022's "Co-Diagnostics: Swinging For The Fences" ("Fences"). I wrote a pair of articles to check out the fundamental story backing up its fine financial metrics. The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.Co-Diagnostics ( NASDAQ: CODX) initially drew my attention because of its stellar A+ quant ratings. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). Ībout Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. ![]() ![]() To learn more about the summit, including in-person and virtual registration details, please visit. In-person visitors are invited to visit the Company at Booth #206. On Monday, August 22, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's forthcoming Co-Dx PCR Home platform, in the conference's Enabling Point-of-Care diagnostics program. The Next Generation Dx Summit offers a valuable window into how point-of-care, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care, and includes three streams: Point-of-Care and Infectious Disease, Companion Diagnostics and Reimbursement stream, and Liquid Biopsy and Early Detection. Co-Diagnostics Official Logo (PRNewsfoto/Co-Diagnostics) (PRNewswire)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |